Drug News

FDA grants emergency use authorisation for Sofia 2 SARS Antigen Test for COVID-19 detection.- Quidel Corp

Read time: 1 mins

Published:11th May 2020

Quidel Corporation announced that it has received Emergency Use Authorization (EUA) from the FDA to market its Sofia 2 SARS Antigen rapid point-of-care test to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid detection of SARS-CoV-2 in nasal or nasopharyngeal specimens from patients meeting the Centers for Disease Control and Prevention’s (CDC) criteria for suspected COVID-19 infection. Sofia 2 is Quidel’s next-generation version of the Sofia instrumented system, utilizing the original Sofia fluorescent chemistry design while improving upon the graphical user interface and optics system to provide an accurate and automated result in 15 minutes.

Condition: Coronavirus/COVID-19 Infection

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA issues emergency use authorisation of Pemgarda (pemivibart) (formerly VYD 222) for pre-exposure prophylaxis of COVID 19,- Invivyd Inc.

Invivyd, Inc. a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced that Pemgarda (pemivibart), formerly VYD 222, a half-life extended monoclonal antibody (mAb), has received emergency use authorization (EUA) from the FDA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination.

3 mins

Drug news

New data from three real-world retrospective studies of Veklury (remdesivir) are presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI)

Gilead Sciences, Inc. announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI)

2 min

Drug news

MHLW (Japan) grants full approval for Xocova ( ensitrelvir) to treatSARS-CoV-2 infection in Japan

Shionogi & Co., Ltd. announced that it has obtained standard approval from the Ministry of Health, Labour and Welfare (MHLW) for Xocova (Generic name: ensitrelvir fumaric acid), a novel anti-SARS-CoV-2 drug for the indication of SARS-CoV-2 infection in Japan

1 min

See all news